Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Combo lymphoma treatment wins FDA approval

The U.S. Food and Drug Administration granted earlier-than-expected approval to Roche Holding AG’s antibody-drug conjugate Polivy for the treatment of patients with advanced lymphoma.

Read More »

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan’s Daiichi Sankyo’s met the main goal in a mid-stage study, bolstering the companies’ position in a highly competitive oncology market.

Read More »

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.

Read More »

Five-Member GO Therapeutics Inks Deal with Roche

GO Therapeutics, with headquarters in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.

Read More »

Celgene Revamps Pact With Sutro Biopharma

Sutro Biopharma and Celgene modified their 2014 immuno-oncology collaboration revolving around four programs that are in preclinical development.

Read More »

Pfizer’s Besponsa Approved in EU

The European Commission approved Besponsa as monotherapy for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

Read More »

Immunomedics, Seattle Genetics ink $2 billion deal

Drug developer Immunomedics Inc. entered into a development and licensing deal worth up to $2 billion for its experimental cancer drug with Seattle Genetics Inc.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom